$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

Opus Genetics, Inc. (IRD)IRD

Opus Genetics, Inc.

$0.98

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

11/20/2024: IRD (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Historic Profit: -51.89%	Upturn Advisory Performance 2	Avg. Invested days: 18
Profits based on simulation	Stock Returns Performance 1	Last Close 11/20/2024

Type: Stock	Today’s Advisory: PASS
Historic Profit: -51.89%	Avg. Invested days: 18
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 11/20/2024	Upturn Advisory Performance 2

Key Highlights

Company Size ETF	Market Capitalization 0 USD
Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -
Volume (30-day avg) 181586	Beta -
52 Weeks Range 0.85 - 3.40	Updated Date 11/10/2024

Company Size ETF	Market Capitalization 0 USD	Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -	Volume (30-day avg) 181586	Beta -
52 Weeks Range 0.85 - 3.40	Updated Date 11/10/2024

Earnings Date

Report Date 2024-11-11	When BeforeMarket
Estimate -0.25	Actual -0.2879

Report Date 2024-11-11

When BeforeMarket

Estimate -0.25

Actual -0.2879

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -
Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -
Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Trailing PE -	Forward PE -	Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Analyst Ratings

Rating 4.75	Target Price -	Buy 1
Strong Buy 3	Hold -	Sell -
Strong Sell -

Rating 4.75	Target Price -	Buy 1	Strong Buy 3
Hold -	Sell -	Strong Sell -

About Opus Genetics, Inc.

Exchange	NASDAQ	Headquaters	Farmington Hills, MI, United States
IPO Launch date	2005-05-23	CEO & Director	Mr. George Magrath M.B.A., M.D., M.S.
Sector	Healthcare	Website	https://opusgtx.com
Industry	Biotechnology	Full time employees	14
Headquaters	Farmington Hills, MI, United States
CEO & Director	Mr. George Magrath M.B.A., M.D., M.S.
Website	https://opusgtx.com
Website	https://opusgtx.com
Full time employees	14

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.